Aspirin discontinuation raises the risk of adverse events in patients with CAD
This article has no abstract so we have provided the first paragraph of the full text.
Despite the well-established benefits of aspirin for patients with coronary artery disease (CAD), it is not unusual for these patients to discontinue the drug, either under the supervision of a physician or unsupervised. To identify the hazards associated with the withdrawal of or noncompliance with aspirin treatment, Biondi-Zoccai et al. carried out a meta-analysis involving 50,279 patients enrolled in six studies, three of which focused on aspirin discontinuation and three on adherence to/compliance with aspirin treatment.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
L-DOPA, dyskinesia and striatal plasticityNature Neuroscience News and Views (01 May 2003)
